STOCK TITAN

Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Zomedica Corp. (NYSE American:ZOM) announced that its Assisi Loop® product line continues to be designated as a Fear Free Preferred Product. Fear Free, a global initiative focused on reducing fear, anxiety, and stress in pets, has reaffirmed its validation of Assisi's targeted pulsed electromagnetic field (tPEMF) technology. This technology is designed to reduce inflammation and pain, accelerate healing, and alleviate canine separation anxiety.

The Assisi Loop® products, including the Assisi Loop Lounge®, are effective for various inflammatory conditions, such as post-surgical recovery, osteoarthritis, internal inflammation, wound care, spinal and nerve disorders, and bone, joint, and soft tissue injuries. The Calmer Canine Anxiety Treatment System® specifically targets the amygdala to reduce canine anxiety.

This continued designation aligns with the increasing demand for non-invasive veterinary care and supports Zomedica's mission to improve the overall quality of life for pets and their owners.

Zomedica Corp. (NYSE American:ZOM) ha annunciato che la sua linea di prodotti Assisi Loop® continua a essere designata come Prodotto Preferito Fear Free. Fear Free, un'iniziativa globale focalizzata sulla riduzione di paura, ansia e stress negli animali domestici, ha riconfermato la sua validazione della tecnologia di campo elettromagnetico pulsato mirato (tPEMF) di Assisi. Questa tecnologia è progettata per ridurre l'infiammazione e il dolore, accelerare la guarigione e alleviare l'ansia da separazione nei cani.

I prodotti Assisi Loop®, compreso l'Assisi Loop Lounge®, sono efficaci per varie condizioni infiammatorie, come recupero post-chirurgico, osteoartrite, infiammazione interna, cura delle ferite, disturbi spinali e nervosi, nonché lesioni a ossa, articolazioni e tessuti molli. Il Calmer Canine Anxiety Treatment System® si concentra specificamente sull'amigdala per ridurre l'ansia nei cani.

Questa ulteriore designazione si allinea con la crescente domanda di cura veterinaria non invasiva e supporta la missione di Zomedica di migliorare la qualità complessiva della vita degli animali domestici e dei loro proprietari.

Zomedica Corp. (NYSE American:ZOM) anunció que su línea de productos Assisi Loop® continúa designándose como Producto Preferido Fear Free. Fear Free, una iniciativa global centrada en reducir el miedo, la ansiedad y el estrés en las mascotas, ha reafirmado su validación de la tecnología de campo electromagnético pulsado dirigido (tPEMF) de Assisi. Esta tecnología está diseñada para reducir la inflamación y el dolor, acelerar la curación y aliviar la ansiedad por separación en los perros.

Los productos Assisi Loop®, incluido el Assisi Loop Lounge®, son efectivos para diversas condiciones inflamatorias, como recuperación postquirúrgica, osteoartritis, inflamación interna, cuidado de heridas, trastornos de la columna y nerviosos, y lesiones en huesos, articulaciones y tejidos blandos. El Calmer Canine Anxiety Treatment System® se enfoca específicamente en la amígdala para reducir la ansiedad en los perros.

Esta designación continua se alinea con la creciente demanda de atención veterinaria no invasiva y apoya la misión de Zomedica de mejorar la calidad de vida general de las mascotas y sus dueños.

조메디카 코퍼레이션(NYSE American:ZOM)은 Assisi Loop® 제품 라인이 계속해서 Fear Free 우선 제품으로 지정되었다고 발표했습니다. Fear Free는 반려동물의 두려움, 불안, 스트레스를 줄이는 데 초점을 맞춘 글로벌 이니셔티브로, Assisi의 목표 지향 전자기 펄스 필드(tPEMF) 기술에 대한 검증을 재확인했습니다. 이 기술은 염증과 통증을 줄이고, 치유를 가속화하며, 개의 분리 불안을 완화하도록 설계되었습니다.

Assisi Loop® 제품, 특히 Assisi Loop Lounge®는 수술 후 회복, 골관절염, 내부 염증, 상처 치료, 척수 및 신경 장애, 뼈, 관절 및 연조직 부상과 같은 다양한 염증 상태에 효과적입니다. Calmer Canine Anxiety Treatment System®은 개의 불안을 줄이기 위해 아미그달라를 특별히 겨냥합니다.

이 지속적인 지정은 비침습적 수의학 치료에 대한 증가하는 수요와 일치하며, 반려동물과 그 주인의 전반적인 생활 질 향상을 위한 조메디카의 사명을 지원합니다.

Zomedica Corp. (NYSE American:ZOM) a annoncé que sa ligne de produits Assisi Loop® continue d'être désignée comme Produit Préféré Fear Free. Fear Free, une initiative mondiale axée sur la réduction de la peur, de l'anxiété et du stress chez les animaux de compagnie, a réaffirmé sa validation de la technologie de champ électromagnétique pulsé ciblé (tPEMF) d'Assisi. Cette technologie est conçue pour réduire l'inflammation et la douleur, accélérer la guérison et soulager l'anxiété de séparation chez les chiens.

Les produits Assisi Loop®, y compris l'Assisi Loop Lounge®, sont efficaces pour diverses conditions inflammatoires, telles que la récupération post-chirurgicale, l'arthrose, l'inflammation interne, les soins des blessures, les troubles spinaux et nerveux, ainsi que les blessures aux os, aux articulations et aux tissus mous. Le Calmer Canine Anxiety Treatment System® cible spécifiquement l'amygdale afin de réduire l'anxiété canine.

Cette désignation continue s'inscrit dans la demande croissante de soins vétérinaires non invasifs et soutient la mission de Zomedica d'améliorer la qualité de vie des animaux de compagnie et de leurs propriétaires.

Zomedica Corp. (NYSE American:ZOM) hat angekündigt, dass ihre Assisi Loop® Produktlinie weiterhin als Fear Free Präferenzprodukt ausgewiesen ist. Fear Free, eine globale Initiative zur Reduzierung von Angst, Stress und Furcht bei Haustieren, hat die Validierung von Assisis gezielter gepulster elektromagnetischer Feldtechnologie (tPEMF) erneut bestätigt. Diese Technologie zielt darauf ab, Entzündungen und Schmerzen zu reduzieren, die Heilung zu beschleunigen und die Trennungsangst bei Hunden zu lindern.

Die Assisi Loop® Produkte, einschließlich des Assisi Loop Lounge®, sind wirksam bei verschiedenen entzündlichen Erkrankungen, wie postoperativer Genesung, Osteoarthritis, innerer Entzündung, Wundpflege, Rücken- und Nervenstörungen sowie Verletzungen an Knochen, Gelenken und Weichgewebe. Das Calmer Canine Anxiety Treatment System® zielt speziell auf die Amygdala ab, um die Angst bei Hunden zu reduzieren.

Diese fortgesetzte Auszeichnung entspricht der steigenden Nachfrage nach nicht-invasiver tierärztlicher Versorgung und unterstützt die Mission von Zomedica, die Lebensqualität von Haustieren und deren Besitzern zu verbessern.

Positive
  • Continued designation as Fear Free Preferred Product, validating Assisi's tPEMF technology
  • Assisi Loop® products effective for a wide range of inflammatory conditions
  • Alignment with increasing demand for non-invasive veterinary care
Negative
  • None.

The designation of Zomedica's Assisi Loop® product line as a Fear Free Preferred Product is moderately positive for the company. While it doesn't directly impact financials, it enhances the product's credibility and market positioning. This validation from a respected industry initiative could potentially boost sales and market share in the competitive veterinary health sector. However, the actual financial impact remains to be seen and will depend on how effectively Zomedica leverages this designation in its marketing and sales strategies. Investors should monitor future earnings reports for any noticeable uptick in revenue from the Assisi product line.

The Fear Free designation for Zomedica's Assisi Loop® is significant in the veterinary world. This recognition aligns with the growing trend towards stress-free veterinary care, which is becoming increasingly important to pet owners. The tPEMF™ technology's ability to address both physical ailments and anxiety positions it uniquely in the market. Its non-pharmaceutical approach is particularly appealing given the rising concerns about over-medication in pets. The wide range of applications - from post-surgical recovery to anxiety treatment - makes it a versatile tool for veterinary practices. This could lead to broader adoption across the industry, potentially driving long-term growth for Zomedica.

This news reflects a strategic alignment with current pet care trends. The pet health market is increasingly focusing on holistic and stress-free treatments, driven by pet humanization trends. Zomedica's Assisi products cater to this demand, potentially giving the company an edge in a growing market segment. The Fear Free designation acts as a form of third-party validation, which can be important in influencing both veterinarians' recommendations and pet owners' purchasing decisions. However, the impact on Zomedica's market position will depend on effective marketing and education efforts to capitalize on this designation. Investors should watch for changes in Zomedica's market share and brand recognition in the coming quarters.

Assisi's tPEMF™ technology aligns with Fear Free's mission to “prevent and alleviate fear, anxiety, and stress in pets”

ANN ARBOR, MI / ACCESSWIRE / August 29, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering therapeutic and diagnostic products for equine and companion animals, is pleased to announce that its Assisi Loop® product line is continuing its designation as a Fear Free Preferred Product. Fear Free, a globally recognized initiative dedicated to reducing fear, anxiety, and stress in pets, reaffirmed its validation of Assisi's targeted pulsed electromagnetic field (tPEMF) technology, which is designed to reduce inflammation and pain, accelerate healing, and alleviate canine separation anxiety.

"The Fear Free organization has had an incredible impact on how veterinary care is delivered," stated Chris Pachel, DVM, DACVB. "They've championed the emotional needs of the animals we care for and have provided high quality education to practitioners and pet owners looking to uplevel their skills. I also appreciate the organization's efforts to partner with companies like Zomedica and the Assisi line of products that are in alignment with their vision and mission, providing visibility and supporting them in the marketplace in that ongoing effort to better the lives of animals. I'm grateful to practice medicine in an era when this focus is at the forefront of our profession."

"The continued inclusion of Assisi products in our Preferred Product Program is a testament to their alignment with our mission to reduce fear, anxiety, and stress in pets," emphasized Alyssa Smith, Head of Corporate Accounts at Fear Free. "The Preferred Product Program offers veterinary professionals reliable tools that enhance the emotional and physical wellbeing of the animals under their care."

"We are delighted to continue our relationship with Assisi. Their dedication to developing innovative, non-pharmaceutical solutions for reducing pain and anxiety aligns perfectly with our mission," explained Randy Valpy, CEO of Fear Free. "Together, we are making significant strides in improving the overall quality of life for pets and their owners."

Larry Heaton CEO of Zomedica, stated, "Veterinarians seeking effective therapeutic solutions that minimize pain and anxiety in pets naturally turn to the Assisi suite of products. The gentle signals generated by the proprietary technology, which can be utilized from the comfort of home, align perfectly with the increasing demand for non-invasive veterinary care."

Assisi Loop® products, including the Assisi Loop Lounge®, are effective for a wide range of inflammatory conditions, including post-surgical recovery, osteoarthritis, internal inflammation, wound care, spinal and nerve disorders, and bone, joint, and soft tissue injuries. The Calmer Canine Anxiety Treatment System® reduces canine anxiety with a tPEMF signal specifically tuned to influence the amygdala, which is the emotional center of the brain. For more information visit Assisi LOOP - Assisi (zomedica.com)

About Fear Free:
Founded by Dr. Marty Becker and developed by hundreds of experts in behavior, medicine, and handling, Fear Free is a global initiative that offers online and in-person education that empowers veterinary professionals, the pet professional community, animal shelter staff and volunteers, and pet owners to create low-stress environments for pets. Fear Free provides both professionals and pet lovers alike with the knowledge and tools to look after a pet's physical and emotional wellbeing, thereby reducing fear, anxiety, and stress in animals during veterinary visits and other interactions, such as grooming, pet sitting, daycare, and boarding visits.

Veterinary or pet professionals can learn more about becoming Fear Free Certified by visiting fearfree.com. Pet owners can visit fearfreehappyhomes.com to access free videos, articles, and more that will help improve the physical and emotional health of their pets right at home. Shelter, rescue, and animal welfare employees and volunteers can visit fearfreeshelters.com to enroll in the complimentary program.

For Fear Free:
Andru Valpy
Marketing & Communications Manager
Email: marketing@fearfree.com
Phone: +1 (306) 226-9086

About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. An NYSE American company, Zomedica grew revenue 33% in 2023 to $25 million and maintains a strong balance sheet with approximately $83 million in liquidity as of June 30, 2024. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: continued growth of sales, the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work; uncertainty as to the timing and results of verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.



View the original press release on accesswire.com

FAQ

What is the Assisi Loop® product line by Zomedica (ZOM)?

The Assisi Loop® product line by Zomedica (ZOM) uses targeted pulsed electromagnetic field (tPEMF) technology to reduce inflammation and pain, accelerate healing, and alleviate canine separation anxiety in pets.

Why has Fear Free designated Zomedica's (ZOM) Assisi Loop® as a Preferred Product?

Fear Free has designated Zomedica's (ZOM) Assisi Loop® as a Preferred Product because its tPEMF technology aligns with their mission to reduce fear, anxiety, and stress in pets, and it provides non-invasive, effective therapeutic solutions for various inflammatory conditions.

What conditions can Zomedica's (ZOM) Assisi Loop® products treat?

Zomedica's (ZOM) Assisi Loop® products can treat a wide range of inflammatory conditions, including post-surgical recovery, osteoarthritis, internal inflammation, wound care, spinal and nerve disorders, and bone, joint, and soft tissue injuries.

How does the Calmer Canine Anxiety Treatment System® by Zomedica (ZOM) work?

The Calmer Canine Anxiety Treatment System® by Zomedica (ZOM) uses a tPEMF signal specifically tuned to influence the amygdala, the emotional center of the brain, to reduce canine anxiety.

Zomedica Corp.

NYSE:ZOM

ZOM Rankings

ZOM Latest News

ZOM Stock Data

130.63M
949.95M
1.76%
8.62%
5.12%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR